Lacy Brian E, Levenick John M, Crowell Michael D
Dr. Lacy is Section Chief of Gastroenterology and Hepatology and Dr. Levenick is a Gastroenterology Fellow in the Division of Gastroenterology and Hepatology at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Crowell is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic in Scottsdale, Arizona.
Gastroenterol Hepatol (N Y). 2012 Oct;8(10):653-60.
Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-1 2% of the US population meet the diagnostic criteria for IBS, and 1 5% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, first-in-class medication for the treatment of chronic constipation and constipation-predominant IBS.
慢性便秘和肠易激综合征（IBS）是功能性胃肠疾病，会显著影响患者的生活质量。慢性便秘和IBS很常见——美国12%的人口符合IBS的诊断标准，15%符合慢性便秘的标准——从经济角度来看，这些病症会对医疗系统产生负面影响。尽管尝试了饮食调整、运动或使用非处方药物，但许多患者仍有持续症状。替代治疗选择有限。本文介绍了利那洛肽（Linzess，Ironwood制药公司/森林制药公司），这是一种用于治疗慢性便秘和以便秘为主的IBS的新型一流药物。
